As part of an NHS Executive Trent regional initiative we considered the role and cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma. The key trials and case series show an additional patient benefit of 0.8-1.1 life years over standard chemotherapy. We estimate incremental cost per life year gained of £12 800-£17 600, which reduces further if long-term benefits are considered. High dose chemotherapy in these conditions is both life-saving and cost-effective.
- intracerebral therapy
- sustained release
- Hodgkin's disease
- high dose chemotherapy
Mairs, R. J., Wideman, C. L., Angerson, W. J., Whateley, T. L., Reza, M. S., Reeves, J. R., ... Neshasteh-Riz, A. (2000). Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model. British Journal of Cancer, 82(1), 74-80. https://doi.org/10.1054/bjoc.1999.0879